A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells.

about

Obinutuzumab-mediated high-affinity ligation of FcγRIIIA/CD16 primes NK cells for IFNγ production.Respiratory Influenza A Virus Infection Triggers Local and Systemic Natural Killer Cell Activation via Toll-Like Receptor 7.The Role of Toll-Like Receptor in Inflammation and Tumor Immunity

P2860

Q37741570-E6648497-924F-458A-9EBC-9FAE54A8D2C4 Q50335684-A60A6A3C-7B4D-4308-AFF4-484A5A581EA6 Q57170572-76810758-C1E0-40D7-B9D9-CAA1B66C9B74

P2860

A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells.

Item

http://www.wikidata.org/entity/Q41000160

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

A TLR7 agonist enhances the an ...... via NK cells and CD4 T cells.

@en

type

Item

label

A TLR7 agonist enhances the an ...... via NK cells and CD4 T cells.

@en

prefLabel

A TLR7 agonist enhances the an ...... via NK cells and CD4 T cells.

@en

P1476

A TLR7 agonist enhances the an ...... via NK cells and CD4 T cells.

@en

P2093

E Fagnano

http://www.w3.org/2001/XMLSchema#string

E J Cheadle

http://www.w3.org/2001/XMLSchema#string

G Lipowska-Bhalla

http://www.w3.org/2001/XMLSchema#string

J Honeychurch

http://www.w3.org/2001/XMLSchema#string

S J Dovedi

http://www.w3.org/2001/XMLSchema#string

P2860

Fcgamma receptors as regulators of immune responses

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.

Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.

Reciprocal regulation of activating and inhibitory Fc{gamma} receptors by TLR7/8 activation: implications for tumor immunotherapy.

Indirect inhibition of Toll-like receptor and type I interferon responses by ITAM-coupled receptors and integrins.

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma

The TLR7 agonist induces tumor regression both by promoting CD4⁺T cells proliferation and by reversing T regulatory cell-mediated suppression via dendritic cells.

Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice.

P2888

leu.2016.352

P304

1611-1621

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2016.352

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Tim M. Illidge

Christian Klein

P577

2016-11-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1046972547

http://www.w3.org/2001/XMLSchema#string

P698

27890931

http://www.w3.org/2001/XMLSchema#string

P921

Toll-like receptor

P932

5508079

http://www.w3.org/2001/XMLSchema#string

A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells.

about

P2860

P2860

A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P921

P932